Influence of thyroid-stimulating hormone on the recurrence after radiofrequency ablation for atrial fibrillation
Keywords:atrial fibrillation, radiofrequency ablation, thyroid-stimulating hormone, recurrence
Atrial fibrillation is one of the most common sustained disorders of cardiac rhythm and is associated with an increased risk of mortality, morbidity due to thromboembolic complications, and heart failure. It is important to highlight that the causative factors are vast. It is well-known that thyroid dysfunction has a proarrhythmic effect and increases the risk of cardiovascular disease. Hyperthyroidism or thyrotoxicosis is recognized to be a baseline risk factor for the development of atrial fibrillation. However, the role of hypothyroidism in atrial arrhythmogenesis is less recognized and not fully understood. At the moment radiofrequency catheter ablation is actively used in the treatment of atrial fibrillation, which in most cases has high efficiency and persistent effect. Despite that, the recurrence of supraventricular tachyarrhythmia can be observed in some patients even after radiofrequency catheter ablation. Patients with a history of hypothyroidism or even high-normal thyroid-stimulating hormone levels are more likely to have a recurrence of supraventricular tachyarrhythmia after radiofrequency catheter ablation. Therefore, thyroid-stimulating hormone levels should be determined in patients who have undergone radiofrequency catheter ablation of atrial fibrillation, especially paroxysmal atrial fibrillation. Consequently, it should be noted that the assessment and correction of modifying risk factors before radiofrequency catheter ablation may provide opportunities for future prevention of recurrence of supraventricular paroxysmal arrhythmias, improve the prognosis and overall quality of life in patients of this group. We have demonstrated the clinical case and emphasized the association of high-normal thyroid-stimulating hormone levels with supraventricular tachyarrhythmia recurrence after radiofrequency catheter ablation for atrial fibrillation.
Chung M.K., Refaat M., Shen W.K. et al. Atrial fibrillation. Journal of the American College of Cardiology. 2020. 75(14). 1689-1713.
Maraj I., Gonzalez M.D., Naccarelli G.V. Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. The Journal of Innovations in Cardiac Rhythm Management. 2018. 9(8). 3274-3281. doi: 10.19102/icrm.2018.090801.
Zoni-Berisso M., Lercari F., Carazza T. et al. Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology. 2014. 6. 213-220. doi: 10.2147/CLEP.S47385.
Sankaranarayanan R., Kirkwood G., Visweswariah R., Fox D.J. How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era. Current Cardiology Reviews. 2015. 11(3). 190-198. doi: 10.2174/1573403x10666140902143020.
Jabbar A., Pingitore A., Pearce S.H. et al. Thyroid hormones and cardiovascular disease. Nature Reviews Cardiology. 2017 Jan. 14(1). 39-55. doi: 10.1038/nrcardio.2016.174.
Passman R. Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation. UpToDate. 2019.
Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. The American Journal of Cardiology. 1998 Oct. 82(8A). 2N-9N. doi: 10.1016/s0002-9149(98)00583-9.
Safaei N., Montazerghaem H., Azarfarin R. et al. Radiofrequency ablation for treatment of atrial fibrillation. BioImpacts. 2011. 1(3). 171-177. doi: 10.5681/bi.2011.023.
Morishima I., Okumura K., Morita Y. et al. High-Normal Thyroid-Stimulating Hormone Shows a Potential Causal Association with Arrhythmia Recurrence After Catheter Ablation of Atrial Fibrillation. Journal of the American Heart Association. 2018. 7(14). e009158. doi: 10.1161/JAHA.118.009158.
Zhang Y., Dedkov E.I., Teplitsky D. et al. Both Hypothyroidism and Hyperthyroidism Increase Atrial Fibrillation Inducibility in Rats. Circulation: Arrhythmia and Electrophysiology. 2013. 6(5). 952-959. doi: 10.1161/CIRCEP.113.000502.
Mujović N., Marinković M., Lenarczyk R. et al. Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians. Advances in Therapy. 2017. 34(8). 1897-1917. doi: 10.1007/s12325-017-0590-z.
Link M.S., Haïssaguerre M., Natale A. Ablation of Atrial Fibrillation: Patient Selection, Periprocedural Anticoagulation, Techniques, and Preventive Measures After Ablation. Circulation. 2016 Jul. 134(4). 339-352. doi: 10.1161/circulationaha.116.021727.
Sharma V. Thyroid hormone levels and risk of atrial fibrillation. American Thyroid Association. 2018. 11 (4). 7.
Baumgartner C., da Costa B.R., Collet T.H. et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017. 136. 2100-2116.
Klein I., Danzi S. Thyroid disease and the heart. Circulation. 2007. 116. 1725-1735.
Calkins H., Hindricks G., Cappato R. et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. Journal of Arrhythmia. 2017. 33. 369-409.
Walsh J.P., Bremner A.P., Bulsara M.K. et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Archives of Internal Medicine. 2005. 165. 2467-2472.
Kim E.J., Lyass A., Wang N. et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). American Heart Journal. 2014. 167. 123-126.
Wei S.B., Wang W., Liu N. et al. U-shaped association between serum free triiodothyronine and recurrence of atrial fibrillation after catheter ablation. Journal of Interventional Cardiac Electrophysiology: an International Journal of Arrhythmias and Pacing. 2018 Apr. 51(3). 263-270. doi: 10.1007/s10840-018-0337-z.
Bruere H., Fauchier L., Bernard Brunet A. et al. History of thyroid disorders in relation to clinical outcomes in atrial fibrillation. The American Journal of Medicine. 2015. 128. 30-37.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.